Study Design: Pilot study to estimate hospital inpatient prices in 10 states by payer and to validate the results using similar information from Medicare and private insurance claims and household survey databases.
Inpatient hospitalizations are one of the most expensive groups of health care services. In 2010, spending on hospital care was projected to account for 37 percent of all health care services and products purchased in the United States; inpatient services accounted for about two-thirds of this spending.
1 Because hospitals operate in a competitive marketplace, little is publicly revealed about the actual revenue, which we refer to as the paid "price" that hospitals receive for an inpatient stay for a specific condition. This lack of available information limits consumers' ability to compare prices with quality of care for the treatment of specific conditions in specific hospitals. The lack of information also limits researchers' ability to investigate the way hospitals set prices for specific services and payers, and the financial implications of payer mix within a competitive market area. With efficiency and quality improvement at the center of health care debates, public information on prices could afford consumers and researchers better access to information with which to evaluate the value of inpatient hospital treatment, and to better understand the revenue streams for, and competition among hospitals in the same market areas.
To address the information gap on hospital price, the Agency for Healthcare Research and Quality (AHRQ) initiated a pilot project to investigate the feasibility of estimating prices received by specific hospitals from major payer groups for each hospital stay. Publicly accessible data on financial transactions for specific types of inpatient stays are usually limited to prices paid by specific government payers such are Medicare or to charges billed to the patient or his insurer. 2 Charges have only limited use in understanding prices received by hospitals because the billed charges are seldom paid in full. Instead, substantial discounts negotiated by private insurers, payment rates imposed by Medicare and Medicaid, and nonpayment by some uninsured patients reduce billed charges to a lower actual paid price that often differs by payer for the same service.
The objective of this pilot study is to present methods used to estimate hospital prices in ten states and to evaluate the results against a variety of other available data sources. We also present more detailed prices by state and sub-state areas for all diagnoses and specific diagnoses to demonstrate the value of providing price information to consumers and researchers.
Methods

Data
The data for this study were derived from the Healthcare Cost and Utilization Project (HCUP) State Inpatient Database (SID) files and hospital financial data from states for 2006. We evaluated source documents and/or consulted with state experts to understand the specific, detailed financial information that was available from 28 HCUP Partner states. The best sets of financial data for our purposes came from states whose data contained: 1) hospital-specific financial information for each major payer (Medicare, Medicaid, private insurance and self-pay); 2) charges and net revenue separately for inpatient and outpatient services for each payer; and 3) financial information for most hospitals in the state. We also looked for states that were geographically diverse and granted AHRQ permission to link the financial data to the HCUP SID and then to publicly report the results at a state or sub-state level.
Healthcare Cost and Utilization Project (HCUP
Our search narrowed to ten states (California, Florida, Massachusetts, Nevada, New Jersey, Virginia, West Virginia, Wisconsin, and two additional states where public release of the information was not possible) that collected the most complete hospital financial information for 2006 for our purposes.
Estimating Hospital Prices
The general method used to estimate inpatient hospital prices was to create payer-specific "price-tocharge ratios" (PCRs) for each hospital using the state financial data collected from hospitals in each state. PCRs were then applied to the HCUP-SID charges to estimate the price of a single hospital stay based on the primary payer and gross charges for that discharge.
Data Validation and Hospital Mapping.
We obtained state financial data and performed checks to ensure that detailed information agreed with statewide totals. 4 There were only a few discrepancies in the data and they were resolved with the state data organization.
We mapped hospitals from the state financial data to those in the HCUP SID. We excluded noncommunity hospitals (rehabilitation hospitals, psychiatric hospitals, Federal hospitals, and long-term care hospitals), California hospitals operating under capitated arrangements that did not report sufficient state financial data, and a few hospitals that could not be matched between the two data sets. Occasionally, summarized data from one data set were matched to a single combined report in the other data set for some hospitals with the same parent organization.
We compared total discharges/admissions and charges in the linked HCUP SID and state financial data to uncover any major discrepancies between the two sources. There were almost no exact matches in counts of discharges/admissions and charges between the data sources. Some of these discrepancies were related to differences in the period covered by the report (fiscal years, rather than calendar years) or in reporting instructions that either excluded or allowed the reporting of long-term care units (such as nursing home units) in hospital statistics. 5 The timing issue should not pose any significant problem in creating PCRs; we did not expect great differences in the PCRs when the timing was offset by several months. The inclusion of nursing home units presented a potential bias to the extent that a payer may discount charges for acute care differently from long-term care, but the actual effect is unknown. While we can identify this issue, we could not adjust the data to account for this.
Estimating PCRs. We defined the "price" of a hospital stay as equal to the revenue received by a hospital from all sources for delivering services for a single inpatient hospitalization. The sum of "prices" for all inpatient discharges in a particular hospital equals the total net inpatient revenue received by the hospital in support of inpatient services. In most states, total inpatient revenue cannot be obtained directly from the hospital financial data, but must be constructed from financial variables: Gross inpatient charges reduced for inpatient contractual adjustments and other uncollected inpatient revenue including bad debt, charity care and other deductions such as employee, courtesy, administrative, and prompt payment discounts. Gross inpatient charges must also be increased for other revenue sources associated with inpatient stays, including Medicaid and Medicare disproportionate share (DSH) payments and other assessments or subsidies for indigent inpatient care as shown in Table 1 .
[Insert Table 1] Although the ten states with hospital financial data selected for this study were states with the most complete data, individual data elements required to construct net inpatient revenues were often not available for each payer. All states reported inpatient gross revenue by payer. Most states also supplied inpatient contractual adjustments for most payers. For other data elements such as bad debt, discounts, charity care, charity pool payments, and government subsidies and grants, states often reported inpatient and outpatient values combined, and usually reported one value for all payers. As these problems with the state financial data were encountered, we developed procedures for estimating splits in these composite inpatient/outpatient and all-payer figures. We devised ratios based on similar data in a group of other states that did report inpatient and outpatient variables separately, and estimated distributions across payers based on a related variable (e.g., charity subsidies distributed to payers based on bad debt distributions by payer, or uncompensated care pool funds distributed to payers based on inpatient gross revenues for Medicaid, other state medical assistance payments, and the uninsured). Most of these estimates were for relatively small portions of deductions or revenue.
The final step was to calculate net revenues for each hospital and each payer using the steps outlined in Table 1 . Net revenues (prices) by payer were then divided by gross revenues (charges) by payer to create a PCR by payer for each hospital.
Calculating Prices. Once the payer-specific PCRs were created, we identified the primary payer for each HCUP-SID discharge and applied the state hospital financial PCR for that payer and hospital to the charges recorded for that stay on the HCUP SID. This created a payer-specific "price" for that discharge. For this study, we defined five uniform payer categories used in HCUP: Medicare, Medicaid, private health insurance, self-pay (including the uninsured), and all other payers.
Analysis
We evaluated our estimated prices by comparing the results against data from other sources that also reported payments by payer for hospital stays. Only a limited number of data sources contain hospital prices by payer: the Medical Expenditure Panel Survey (MEPS) sponsored by AHRQ that surveys a sample of households for their medical expenditures; the Thomson Reuters MarketScan® commercial claims database; and Medicare claims databases from the Centers for Medicare and Medicaid Services (CMS). Only Medicare claims could be tabulated on a state basis for the ten states used in this study.
For all data sources, we also calculated nationwide average prices. The results of these comparisons are shown in Table 2 . Our overall assessment is that our HCUP average prices for hospitalizations in the United States fall within reasonable ranges of prices from other survey and claims data sources for all payers, Medicare, Medicaid, and private insurance in 2006.
[Insert Table 2] HCUP. Table 2 shows the prices calculated by multiplying estimated PCRs from the state financial data by HCUP charges. The overall average price of a hospital stay in 2006 was $8,704 across 10 states. The average prices paid by Medicare and private insurance were higher than the all-payer average and those paid by Medicaid, self-pay (including the uninsured) and other payers were lower than the all-payer average. Self-pay average prices were very low because many people without insurance pay little if any of their hospital bill. Among payers, average prices for Medicare stays ($10,450) were highest, followed by prices paid by private insurance ($9,254), Medicaid ($7,236) , and all other insurers ($4,113). Prices paid directly by individual consumers ($1,636) were the lowest.
Medical Expenditure Panel Survey (MEPS).
MEPS is a household survey that collects health care event information from a sample of almost 12,811 households that included 32,577 individuals in 2006. The average payments reported by MEPS are generally similar to HCUP prices, but this difference varies by payer. All-payer average payments reported by MEPS ($8,888) are 2 percent higher than our pilot study results ($8,704) . By payer, MEPS Medicare and Medicaid average prices are 7 to 8 percent lower than our pilot study results. MEPS private health insurance average payments are 5 percent higher than our study results, while the MEPS average prices for both self-pay and other payers are one to three times those estimated in the pilot study. Similar to our pilot study results, Medicare and private insurance pay the highest average price per stay, and self-pay the lowest.
MarketScan.® The Thomson Reuters MarketScan commercial claims database comprises data from approximately 30 million covered lives (employees and dependents) each year who received their coverage through approximately 140 employers and regional health plans. Many of the employer plans included in MarketScan come from large, self-insured employers with generous benefit coverage.
We created a high and low average price for a privately insured hospitalization because we cannot identify with certainty the stays where private insurance was the primary payer. The higher price is the result of taking all payments made by private insurers and dividing them by each stay where private insurance comprised 50 percent or more of all expected payments, thus identifying most, but not all stays where private insurance was the primary payer. The lower average price was calculated by dividing all private insurance payments by all discharges with any amount of payment from private insurance, which may underestimate the average price.
MarketScan private insurance average prices ranged from 14 percent below to 12 percent above our pilot study results ($7,957-$10,337 in MarketScan compared to pilot study results of $9,254).
Medicare. Medicare claims come from the CMS Standard Analytic File (SAF) database of hospital claims and exclude final payment settlements that take place subsequent to reimbursement, usually through the submission of Medicare Cost Reports. The Medicare average reimbursement in our ten HCUP states ($9,643) is, as expected, somewhat lower (by 8 percent) than our HCUP-estimated Medicare prices ($10,450).
Medicare SAF is the only database where we can accurately assess the average prices of our ten HCUP states against all states. For Medicare, this information shows that average Medicare prices in our ten HCUP states ($9,643) are 10 percent higher than the all-state Medicare average price ($8,752) from the same database. If this also holds true for other payers, then this fact may also explain some of the price differential between MEPS and HCUP.
Results
Estimated State and CBSA Prices. Given the nationwide comparisons and an understanding of major caveats and assumptions, we can examine and assess estimated prices by payer for state and selected diagnoses and for all diagnoses for Core Based Statistical Areas (CBSAs) within our ten states. Figure 1 shows average inpatient stay prices for four common conditions (heart attack, pneumonia, septicemia, and diabetes mellitus with complications) and for all conditions based on HCUP-SID estimated prices. In each of these conditions, Medicare, Medicaid, and private insurance prices are close to or above the all-payer average and the prices for self-pay and all other payers are substantially below the all-payer average. However, across all diagnoses, the average payments exhibit a slightly different pattern in that the average price for Medicaid hospitalizations was lower than the all-payer average for all diagnoses. This difference in the average price pattern for Medicaid is because about one-quarter of all Medicaid stays are for lower-price maternal and newborn stays in community hospitals, which are not shown as a separate diagnosis in this figure.
[Insert Figure 1 ] Table 3 shows the average prices for four common conditions depicted in Figure 1 at the state level. Prices vary dramatically by state and payer for the same condition. The range in prices can be attributed to a variety of factors, including age, gender and severity mix of the population receiving treatment, the degree of competition in an area, costs (such as wages and energy prices) in providing services, statespecific coverage and payment policies for Medicaid, and the share of the population that is uninsured. Table 3 also shows average prices for pneumonia, septicemia, diabetes mellitus with complications, and all diagnoses for our ten HCUP states.
[Insert Table 3 ] Table 4 shows the range of prices by selected Core Based Statistical Areas (CBSAs) in our ten states. Even within an individual state, the range of prices among areas was considerable overall and for specific payers. For example, in Massachusetts, average prices for all payers ranged from $6,667 in the New Bedford/Fall River Massachusetts portion of the Providence/New Bedford/Fall River CBSA to $10,436 in the Massachusetts portion of the Boston/Cambridge/Quincy CBSA-almost a 60 percent difference. Similar differences can be seen among other payers in the same two Massachusetts CBSAs: Medicare (43 percent), Medicaid (59 percent), and private insurance (73 percent).
[Insert Table 4 ]
Discussion
In evaluating our estimated prices compared to other data sources, there are a number of reasons specific to the data sources that explain the small differences that we observed. In this section we will discuss these issues and present a few limitations and caveats to understand in using our estimated prices. We also present our estimated prices by state and sub-state areas for some sample diagnoses.
MEPS.
There are some general reasons why MEPS prices will differ from HCUP prices for all payers and specific payers. First, MEPS is a survey that comes from a sample of household respondents, and as such has a sampling variance. Because MEPS is a household survey, it also depends on individual respondents to identify all medical events. Missed events do occur, although less frequently for hospital inpatient stays than for other types of events. In addition, MEPS excludes certain groups of people from its sample, including nursing home residents and active duty military, and experiences underreporting of certain high-cost cases and Medicare and uninsured stays (Selden and Sing 2008) . Further, MEPS does not collect information on certain administrative costs associated with Medicaid and Medicare, including Medicaid disproportionate share payments (DSH) made to certain hospitals serving a large percentage of Medicaid and uninsured patients, Medicare DSH, and other revenue adjustments that take place outside of claims transactions such as receipt of state and local government hospital subsidies. These payments would be excluded from MEPS but included in our pilot study prices, resulting in higher estimated prices for some payers using our methods.
MarketScan. Because a sizable portion of insured patients in the MarketScan database is comprised of retired persons covered by Medicare, private insurance will often be the secondary payer for the stay, with Medicare as the primary payer. Therefore, the higher average price calculation should be closer to our estimated average price than the lower price calculation. However, even the higher price calculation may slightly undercount some stays with private insurance as a primary payer, making the higher end of the range of MarketScan prices slightly overstated. In addition, many of the employer plans included in MarketScan come from large employers with generous benefit coverage, which will also make their average prices higher than overall insurance prices.
Medicare. Average prices based on Medicare claims are likely understated because final payment settlements take place subsequent to payment transactions, usually through the submission of Medicare Cost Reports.
There are two additional limitations and caveats to understand about our results.
Aligning Charges and Prices. In hospital financial data, the payer categories are defined by the state's accounting system and usually differ in some aspect from state to state. The amount of estimation required to calculate net revenue by payer varied among states, as did the extent of reported government payments to hospitals to support charity care and bad debt. Moreover, the alignment between charges and net revenue by payer affected the PCRs when multiple insurers paid for one hospitalization. For example, charges are usually assigned to a single primary payer such as Medicare. However, actual revenues received for that stay might be counted in multiple payer categories, such as Medicare and private insurance when private insurance was a secondary payer. The effect is that the revenues by payer may not align completely with the charges by primary payer, distorting the PCRs and affecting our interpretation of the results. This misalignment produced negative PCRs for some hospitals and therefore negative "prices" for self-pay and also occasionally for other payers. Negative
PCRs resulted from the assignment of certain deductions from revenue to specific payers that were greater than the charges assigned to that primary payer. For example, bad debt deductions were assigned only to private insurance (for unpaid copayments and deductibles) and self-pay, while charity care deductions were assigned entirely to self-pay. To the extent that bad debt and charity care deductions from revenue were really offsetting charges assigned to other payers, assigning all or part of these deductions to self-pay overstated the deduction from self-pay and created negative PCRs and prices in some hospitals. For Medicare, Medicaid and private insurance, missing bad debt and charity care deductions from revenue probably led to slightly higher PCRs because the copayments and deductibles that may not have been paid were usually much smaller than the payments by the primary insurer. However, because self-pay and all other payers are relatively small payer categories (4 percent and 5 percent of all hospital revenue, respectively), the deduction from revenues assigned to these payers did, in some cases, have a substantial impact on these PCRs, making them lower and producing negative values for self-pay in some hospitals.
Payer PCR Assumption. A major assumption in this study is that each payer in a single hospital discounts charges to the same extent regardless of diagnosis. A study by Ginsburg notes that payments to hospitals by private insurers are usually based on one of three methods: markups of Medicare diagnosis related groups (DRGs) rates, per diem rates (usually preferred by managed care insurers), or negotiated discounts off of charges (Ginsburg 2010) . Various studies suggest that charge markups can vary substantially over the cost to produce a service, with newer high-cost technology services receiving lower percentage markups over cost than long-established services or supplies and pharmacy products (Dobson et al. 2005; Dalton 2007 ). This suggests some variation in the price received compared to the charge for specific services within the same hospital, which could affect our estimated prices. The extent of this effect in our study is unknown.
Conclusion
As the largest portion of all health care spending, inpatient hospitalizations deserve much attention in any debate on health care expenditures, slowing spending growth, and assessing value received for that spending. As demonstrated in this article, the availability of hospital-and payer-specific prices for specific conditions at the state or sub-state level in a single database provides a rich information source for consumers and researchers.
This study has shown that hospital prices can be reasonably estimated for most major payers by merging data sets collected by states for different purposes. Despite the challenges in identifying appropriate financial data available from states, creating a standardized multi-state data set of financial variables, and linking financial data to administrative discharge information, the prices estimated in this project appear to be reasonably valid when validated against other data sources for most payers. The results illustrate the differences among hospitals in prices received by payer for their services. There was also a considerable variation in prices among states, across diagnoses, and across CBSAs within a state.
Hospital inpatient prices fill an important gap in information that could increase the transparency of the health care system to consumers if this information is made publicly available. Estimated prices would allow researchers to study pricing policies for particular services, and how those policies vary based on the mix of payers, hospital characteristics, case mix and competition within the local market. Prices would also help researchers to understand the ability of private insurers to influence prices paid based on the hospital financial and other characteristics, and to track that influence over time. Prices could also make cost-shifting among payers more transparent. The differential in prices plays a fundamental role in the financial margins of hospitals and their ability to survive in their local marketplace.
Estimating prices in an all-payer database such as HCUP would provide researchers with nearnationwide information for all payers, and their results may further policymakers' understanding of the patterns in geographic variations in spending for all payers. Understanding these factors as hospitals begin to comprehend and adapt to forthcoming regulations under the Affordable Care Act (ACA) would allow policy makers to react more knowledgably to unforeseen effects of the ACA on the hospital system.
Future Directions
This pilot study shows promising results for estimating prices. Next steps could include the expansion of this pilot to additional states to test the extent to which these methods are generalizable to a broader array of states. Predictive models could also be developed to estimate PCRs for states that do not collect financial information. Ideally, AHRQ could expand their list of HCUP tools to include hospital-and payer-specific PCRs that could be used to estimate prices in all HCUP states. 
